After Schedule I: Federal Psychedelic Rescheduling and the Impact on State Law

PROVIDE EMAIL FOR ACCESS

DESCRIPTION

Monday, November 17 | 1:00 - 2:00 pm (PT) | Zoom
BCLT Life Sciences Law & Policy Center

1.00 General CLE Credit Available

Program Info | Resources

Psychedelics have long been legally inaccessible. That might change soon. Join us as we explore the complex legal and regulatory pathway for psychedelic drug rescheduling. As promising clinical trial data for substances like psilocybin and MDMA emerges, a critical question remains: how should these compounds move from Schedule I of the Controlled Substances Act to become accessible medical treatments?

This discussion aims to demystify the rescheduling process and the central role of the FDA in that evaluation, featuring experts from the Multidisciplinary Association for Psychedelic Studies (MAPS), Porta Sophia, and New Approach PAC. We will also analyze the downstream consequences, including how state-level "trigger laws" might automatically — or fail to automatically — conform to a new federal schedule, creating a complex patchwork of state and federal legality.

SPEAKERS

Vincent Joralemon
Director, Life Sciences Law & Policy Center, BCLT, UC Berkeley Law

Ismail L. Ali
Co-Executive Director, MAPS

Graham Pechenik
Founder, Calyx Law

Shahin Shams
Data and Patent Analyst, Porta Sophia

Tamar Todd
Lecturer, UC Berkeley Law

INFO

• Avail. Until: 6/1/2028
• Course Time:   1:00 PM PT
• Duration:   60 min.
• Program Code:   BCLT0067